EDEN LEE: Open Payments
NPI 1023103215 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$511 in 18 payments from 9 companies in 2025. Trend: 2023 $388 · 2024 $342 · 2025 $511
Food & beverage: $511
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $112 |
| Sumitomo Pharma America, Inc. | 1 | $109 |
| Janssen Pharmaceuticals, Inc | 4 | $108 |
| Alkermes, Inc. | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $14 |
Products named: INGREZZA, GEMTESA, INVEGA SUSTENNA, ARISTADA, COBENFY, REXULTI, VRAYLAR, UZEDY.
Industry payments across NV — which companies pay providers there.
